Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR

Annals of Hematology

Volumn 95, Issue 5, 2016, Pages 739-744

  Waterhouse, Miguel ^a   Follo, Marie ^a   Pfeifer, Dietmar ^a   von Bubnoff, Nikolas ^a   Duyster, Justus ^a   Bertz, Hartmut ^a   Finke, Jürgen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Digital PCR; JAK2 V617F

Indexed keywords

JANUS KINASE 2; FLUORESCENT DYE; JAK2 PROTEIN, HUMAN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; BONE MARROW; CONTROLLED STUDY; DIGITAL DROPLET POLYMERASE CHAIN REACTION; ERYTHROCYTE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MUTATIONAL LOAD; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NUCLEIC ACID ANALYSIS; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA; AGED; AMINO ACID SUBSTITUTION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICES; DNA MUTATIONAL ANALYSIS; ENZYMOLOGY; GENETICS; LABORATORY DIAGNOSIS; MIDDLE AGED; MISSENSE MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; PROCEDURES;

AGED; AMINO ACID SUBSTITUTION; BONE MARROW; DNA MUTATIONAL ANALYSIS; FALSE POSITIVE REACTIONS; FEMALE; FLUORESCENT DYES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYMERASE CHAIN REACTION; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84959325578     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2623-0     Document Type: Article

References (13)

1. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397
2. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng J Med 352:1779–1790
3. Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, pp 40–50
4. Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037–2040
5. Paradanani A, Gotlib JR, Jamieson C et al (2011) Safety and efficacy of TG 101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29:789–796
6. Merker JD, Jones CD, Oh ST et al (2010) Design and evaluation of a real-time PCR for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 12:58–64
7. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 79:508–515
8. Taly V, Pekin D, Benhaim L et al (2013) Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59:1722–1731
9. Kinz E, Leiherer A, Lang AH, Drexel H, Muendlein A (2015) Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR. Int J Lab Hematol 37:217–224
10. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8:135–160
11. Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB 018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Eng J Med 363:1117–1127
12. vV617F mutation in philadelphia-negative chronic myeloproliferative neoplasms. Int J Lab Hematol. doi:10.1111/ijlh.12404
13. Lange T, Edelmann A, Siebolts U et al (2013) JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 98:722–728